A new potential strategy for cutaneous squamous cell carcinoma treatment by generating serum-based antibodies from...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Current cancer treatments face challenges like tumor relapse, drug resistance, and low efficiency due to immune evasion.
• Tumor cells adapt to the host immune microenvironment, hindering effective treatment outcomes.

Purpose of the Study:

• To develop and evaluate a novel cancer immunotherapy strategy using serum-based antibodies against mouse cutaneous squamous cell carcinoma (mCSCC).
• To assess the efficacy of this serum therapy in reducing tumor volume and altering specific protein expressions.

Main Methods:

• Mouse cutaneous squamous cell carcinoma (mCSCC) cells were cultured and used to immunize healthy mice, generating anti-tumor antibodies in their serum.
• Therapeutic serum was extracted and administered to tumor-bearing mice.
• Enzyme-linked immunosorbent assay (ELISA) was employed to quantify levels of p53, Bcl-xL, NF-κB, and Bax.

Main Results:

• The serum-based immunotherapy significantly reduced tumor volume in treated mice.
• Treatment reversed alterations in the expression levels of p53, Bcl-xL, NF-κB, and Bax.
• The study demonstrated the potential of serum-derived antibodies as a therapeutic agent.

Conclusions:

• A novel immunotherapeutic strategy using serum antibodies was successfully developed for mCSCC treatment.
• The findings suggest this approach can effectively reduce tumor burden and modulate key molecular markers.
• Further research is warranted to elucidate the precise mechanisms underlying this serum treatment's efficacy.